| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 196,218 | 208,481 | ||
| Accounts receivable | 10,000 | 1,617 | ||
| Prepaid expenses | 6,653 | 6,700 | ||
| Other current assets | 2,617 | 6,758 | ||
| Total current assets | 215,488 | 223,556 | ||
| Property and equipment, net of accumulated depreciation of 48,755 and 46,329 as of september 30, 2025 and december 31, 2024, respectively | 8,196 | 9,037 | ||
| Operating lease right-of-use assets | 13,876 | 15,250 | ||
| Restricted cash | 3,796 | 3,784 | ||
| Other assets | 22 | 728 | ||
| Total long-term assets | 25,890 | 28,799 | ||
| Total assets | 241,378 | 252,355 | ||
| Accounts payable | 14,490 | 14,664 | ||
| Accrued expenses and other current liabilities | 16,487 | 13,026 | ||
| Current portion of deferred revenue | 46,525 | 51,582 | ||
| Current portion of operating lease liability | 8,394 | 8,136 | ||
| Total current liabilities | 85,896 | 87,408 | ||
| Deferred revenue, net of current portion | 11,681 | 4,232 | ||
| Operating lease liability, net of current portion | 11,378 | 13,575 | ||
| Total long-term liabilities | 23,059 | 17,807 | ||
| Total liabilities | 108,955 | 105,215 | ||
| Series a preferred shares, no par value 3,901,348 shares issued and outstanding at september 30, 2025 and december 31, 2024 | 7,874 | 7,874 | ||
| Ordinary shares, no par value 160,288,481 and 153,037,286 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 1,223,721 | 1,191,029 | ||
| Additional paid-in capital | 174,075 | 167,603 | ||
| Accumulated other comprehensive loss | -190 | -161 | ||
| Accumulated deficit | -1,273,057 | -1,219,205 | ||
| Total shareholders' equity | 124,549 | 139,266 | ||
| Total liabilities, series a preferred shares, and shareholders' equity | 241,378 | 252,355 | ||
Wave Life Sciences Ltd. (WVE)
Wave Life Sciences Ltd. (WVE)